Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Acthar

- PMLiVE

US health department proposes three new models to help lower cost of drugs

One suggested model includes offering some essential generic drugs for $2 a month

- PMLiVE

Mallinckrodt files for bankruptcy protection in the US

Bankruptcy filing will reduce debts related to legal liabilities

- PMLiVE

US piles pressure on Mallinckrodt over alleged Acthar fraud

Drugmaker allegedly underpaid rebates owed to Medicaid

- PMLiVE

Mallinckrodt reaches tentative $1.6bn opioid settlement

Agreement reached with a plaintiff's executive committee

- PMLiVE

Mallinckrodt offloads CDMO for $250m

Move follows US opioid settlement

- PMLiVE

Humana lawsuit targets Mallinckrodt’s ‘billion-dollar golden goose’

Latest twist in long story of Acthar

- PMLiVE

Mallinckrodt doses first patient in muscular dystrophy trial

Repurposed drug could help delay decline in muscle function

- PMLiVE

Mallinckrodt pays $1.2bn for Sucampo Pharma

The Irish group will acquire Amitizia, Rescula and a pipeline of rare disease projects

- PMLiVE

Ireland’s Mallinckrodt buys US regenerative medicine firm

Stratatech’s StrataGraft in phase III testing for burns treatment

- PMLiVE

Pfizer settles US Protonix lawsuit for $785m

US government deal covers Wyeth’s failure to pay drug rebates

- PMLiVE

US government probes Lilly and Merck over drug pricing

Department of Justice investigates drug pricing with regard to Medicaid programme

- PMLiVE

Ireland’s Mallinckrodt makes $1.3bn immunotherapy purchase

Will acquire Therakos to further boost its hospital drug portfolio

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links